ASCO26: In vivo oncology approaches continue to show promise
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting…
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting…
During the American Society of Clinical Oncology (ASCO) meeting 2026, data were presented for a number of cancer vaccines, including…
Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting.…
Following news that started brewing last week, Dr Marty Makary has officially resigned from his post as commissioner of the…
Eli Lilly and Eisai have backed their Alzheimer’s disease drugs despite research finding the mechanism of action may be less…
Amazon Web Services (AWS) is launching an artificial intelligence (AI) application to design and test novel drugs more quickly and…
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
Stakeholders in the rare disease development community say that new guidance documents, released by the US Food and Drug Administration…
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining…
Ionis’ Tryngolza (olezarsen) is set to become the company’s first wholly owned blockbuster drug, CEO Brett Monia believes. Speaking at…